20(S)-Ginsenoside Rh2 overcomes gemcitabine resistance in pancreatic cancer by inhibiting LAMC2-Modulated ABC transporters
Introduction: Gemcitabine (GEM) is the first-line drug for pancreatic ductal adenocarcinoma (PDAC), but drug resistance severely restricts its chemotherapeutic efficacy. Laminin subunit γ2 (LAMC2) plays a crucial role in extracellular matrix formation in the development of GEM-resistance. However, t...
Saved in:
| Main Authors: | Yulin Wu, Juan Zhang, Yuanyang Tian, William Chi Shing Cho, Hong-Xi Xu, Zhi-Xiu Lin, Yan-Fang Xian |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Journal of Advanced Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2090123224003904 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inhibitory Effect of Exosomes Loaded with Ginsenoside Rh2 on Growth of Hepatocellular Carcinoma Cells
by: Meile LI, et al.
Published: (2025-07-01) -
Nanoparticle conjugation of ginsenoside Rh2 enhanced antitumor efficacy on hepatocellular carcinoma
by: Fengkai Sun, et al.
Published: (2025-08-01) -
Ginsenoside Rh2 repressed the progression of prostate cancer through the mitochondrial damage induced by mitophagy and ferroptosis
by: Zhen He, et al.
Published: (2025-08-01) -
Ginsenoside Rh2 inhibits breast cancer cell growth via<?A3B2 ACK?>ERβ-TNFα pathway
by: Peng Kunjian, et al.
Published: (2022-05-01) -
Biosynthesis of a Novel Ginsenoside with High Anticancer Activity by Recombinant UDP-Glycosyltransferase and Characterization of Its Biological Properties
by: Dandan Wang, et al.
Published: (2025-02-01)